Details for Patent: 7,326,691

Title:	Compositions comprising amphotericin B, methods, and systems
Abstract:	A composition includes particles including at least about 95 wt % of amphotericin B, wherein the particles have a mass median diameter ranging from about 1.1 .mu.m to about 1.9 .mu.m. Another composition also includes particles including at least about 95 wt % of amphotericin B, wherein at least about 80 wt % of the particles have a geometric diameter ranging from about 1.1 .mu.m to about 1.9 .mu.m. Yet another composition includes particles including amphotericin B, wherein the particles have a mass median diameter less than about 1.9 .mu.m, and wherein the amphotericin B has a crystallinity level of at least about 20%. Unit dosage forms, delivery systems, and methods may involve similar compositions.
Inventor(s):	Duddu; Sarma (Redwood City, CA), Palakodaty; Srinivas (Foster City, CA), Lechuga-Ballesteros; David (San Jose, CA), Miller; Danforth (San Carlos, CA), Kugler; Alan R. (Montara, CA), Frantz; Christopher (Sunnyvale, CA), Tan; Trixie (Daly City, CA), Malcolmson; Richard (San Mateo, CA), Washco; Keith (Fremont, CA), Sweeney; Theresa (El Granada, CA), Tarara; Thomas E. (Burlingame, CA), Dwivedi; Sarvajna (Redwood City, CA), Eldon; Michael A. (Redwood City, CA)
Assignee:	Nektar Therapeutics (San Carlos, CA)
Filing Date:	Jun 21, 2005
Application Number:	11/158,332
Claims:	1. A composition, for localized delivery to the lungs as a powder, the composition consisting essentially of: particles comprising at least about 95 wt % of amphotericin B, wherein the particles comprise a crystallinity level of at least about 20%, a mass median diameter from 1.1 .mu.m to 1.9 .mu.m, and wherein at least about 80 wt % of the particles have a geometric diameter from 1.1 .mu.m to 1.9 .mu.m. 2. The composition of claim 1, wherein the amphotericin B has a crystallinity level of at least about 70%. 3. The composition of claim 1, wherein the amphotericin B has a crystallinity level of at least about 90%. 4. The composition of claim 1, wherein the amphotericin B has a crystallinity level ranging from about 50% to about 99%. 5. A composition, for localized delivery to the lungs as a powder, the composition consisting essentially of: particles comprising at least about 95 wt % of amphotericin B, the amphotercin B comprising a crystallinity level of at least about 70%, and wherein at least 80 wt % of the particles have a geometric diameter from 1.1 .mu.m to 1.9 .mu.m. 6. The composition of claim 5, wherein the amphotericin B has a crystallinity level of at least about 90%.